Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PRLX 93936: Phase I started

Prolexys began an open-label, dose-escalation, U.S. Phase

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE